Cadrenal Therapeutics GAAP EPS of -$1.87

2 hours ago 1

Cadrenal Therapeutics press release (NASDAQ:CVKD): Q2 GAAP EPS of -$1.87.
On June 30, 2025, Cadrenal had cash and cash equivalents of $5.6 million, compared to $10.0 million as of December 31, 2024. The Company had approximately 2.0 million shares of common stock outstanding as of June 30, 2025.

Recommended For You